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Abstract: In July 2006 Atripla™ was approved by the US Food and Drug Administration (FDA), 
combining the active ingredients of one NNRTI and two NRTIs. Atripla™ is the ﬁ  rst “one-pill- 
daily” regimen licensed for the treatment of HIV-1 infection in patients older than 18 years. 
H was licensed in Europe in December 2007 Atripla™ contains efavirenz 600 mg, emtricitabine 
200 mg, and tenofovir disoproxil fumarate 300 mg. It therefore combines 3 compounds which 
have been widely used before and which were recommended for initial therapy due to their 
potency, tolerability, and safety proﬁ  le. Efﬁ  cacy and safety data of efavirenz, tenofovir DF, and 
emtricitabine are reviewed and compared with other antiretroviral drugs, which are used as 
initial therapy for treatment-naive patient.
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Background
It is almost 25 years since in 1983 the human immunodeﬁ  ciency virus type I (HIV-1) was 
deﬁ  ned as the primary cause of the acquired immunodeﬁ  ciency syndrome (Barré-Sinoussi 
et al 1983; Gallo et al 1984). Worldwide, the number of HIV-1 infected persons exceeds 
33 million, the majority of whom live in the developing countries of Sub-Saharan Africa, 
Asia, and South America. With the introduction of protease inhibitors and non-nucleotide 
reverse transcriptase inhibitors to antiretroviral treatment regimens between 1995 and 
1996, the so-called highly active antiretroviral therapy (HAART) was established result-
ing in a dramatic decrease in the mortality and morbidity of HIV infection. Nevertheless 
eradication of the virus still remains impossible. This implies that besides efﬁ  cacy of 
antiretroviral therapy, health care providers have to focus on long-term toxicity, develop-
ment of drug resistances, and tolerance by the patient, leading to an improved long-term 
adherence behavior. It has therefore been a goal of the pharmaceutical industry to reduce 
the daily pill-burden and to simplify antiretroviral therapy by developing a “one-pill-
daily” regimen. To achieve this goal Bristol-Myers Squibb Co. and Gilead Sciences Inc. 
formed a joint venture, and in July 2006 Atripla™ was approved by the US Food and Drug 
Administration (FDA), combining the active ingredients of one non-nucleoside reverse 
transcriptase inhibitor, efavirenz, and two nucleoside reverse transcriptase inhibitors, 
tenofovir disoproxil fumarate (DF) and emtricitabine, all well-known substances. H was 
licensed in Europe in December 2007.
As of October 2007 there were 31 compounds and combinations formally approved 
by the FDA for the treatment of HIV infections. These compounds can be classiﬁ  ed 
in 6 categories according to their point of intervention with the HIV replicative cycle: 
nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase 
inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs), fusion inhibitors (FIs), CCR5-chemokine receptor antagonists, and 
recently approved the integrase inhibitors.
While HAART originally consisted of a pill burden of 20–30 pills per day, this has 
been gradually diminished over the past few years. Fixed drug formulations combin-
ing 2 or 3 NRTIs, eg, Combivir®, Trizivir®, Kivexa®, or 2 PIs, eg, Kaletra®, became Therapeutics and Clinical Risk Management 2008:4(4) 574
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available and simpliﬁ  ed therapy regimens. Nevertheless 
because most HIV-infected patients are likely to require 
prolonged and continuous antiretroviral therapy, there was 
a need for simpler, once-daily, well-tolerated regimens with 
minimal long-term toxicity and durable efﬁ  cacy.
Current US and European guidelines favor backbone 
combination therapy consisting of 2 NRTIs plus either an 
NNRTI or a boosted PI (NIH 2007, EACS 2007). Tenofovir 
DF or zidovudine plus emtricitabine or lamivudine form the 
dual NRTI backbone in recommended NNRTI- or PI-based 
regimens. Except in women who currently are, or wish to 
become, pregnant efavirenz is the NNRTI of choice while 
ritonavir-boosted lopinavir (or low-dose ritonavir with ata-
zanavir, saquinavir) are the PIs of choice.
The new “one-pill-daily” combination Atripla™ 
contains: efavirenz 600 mg, emtricitabine 200 mg, and 
tenofovir DF 300 mg. It therefore combines 3 compounds 
which have been widely used before and which were 
recommended for initial therapy because of its excellent 
potency, tolerability and favorable safety proﬁ  le. We review 
relevant efﬁ  cacy and safety data of efavirenz, tenofovir DF, 
and emtricitabine compared with other common alterna-
tive drugs, which are used as initial therapy in treatment-
naive patient.
Efavirenz
Of all three compounds included in Atripla™, efavirenz 
has been available the longest and was the third NNRTI 
approved. The 006 Study in 1999 showed a superiority of 
efavirenz over indinavir (each given in combination with 
AZT + 3TC) (Staszewski et al 1999). Since then, efavirenz 
has been compared with other drugs in many large random-
ized studies. In general efavirenz showed better efﬁ  cacy, 
as observed in the CLASS study, where efavirenz, used in 
combination with ABC + 3TC, was more effective than d4T 
or boosted amprenavir (Bartlett et al 2002). The ACTG 5095 
study showed superiority of efavirenz over abacavir when 
used in combination with AZT + 3TC (Gulick et al 2004). 
The ACTG 384 trial showed a better efﬁ  cacy of efavirenz 
compared with nelﬁ  navir (Robbins et al 2003; Shafer et al 
2003), whereas in AI424-034 efavirenz was not superior but 
at least comparable to atazanavir (Squires et al 2004). More 
recently the ACTG 5142 trial evaluated 3 different 2-class 
antiretroviral regimens in 753 treatment-naive patients: 
efavirenz + 2 NRTIs; lopinavir/ritonavir + 2 NRTIs; lopina-
vir/ritonavir plus efavirenz. ACTG 5142 could demonstrate 
the superiority of efavirenz to lopinavir/ritonavir in terms 
of time to virological failure and suppression of HIV RNA 
to below 50 copies/mL. However, the efavirenz arm did not 
achieve quite as robust a CD4 count increase as the other two 
arms (Zuger 2006; Riddler et al 2006).
Efavirenz is well tolerated, but mild to moderate CNS 
side effects including dizziness and numbness are typical and 
appear relatively often in the ﬁ  rst days to weeks of treatment. 
Although these symptoms seem to resolve during the course 
of treatment, mild effects may persist (Lochet et al 2003; 
Arendt et al 2007). It therefore has to be decided in each 
case if efavirenz should be replaced or if the patient is able 
to tolerate those symptoms. Another disadvantage should be 
mentioned: the rapid development of drug resistance when 
efavirenz is used as monotherapy or quasi-monotherapy 
due to failure of viral suppression by the backbone drugs. 
Once mutations like the point mutation at position 103 
(K103N) occur, it indicates resistance towards all approved 
NNRTIs. Only the new NNRTI TMC 125, which is still in 
the approval process, seems to be unaffected by those muta-
tions. One possible explanation for the rapid development of 
resistance mutations is the long half-life of NNRTIs (Muro 
et al 2005).
Tenofovir DF
Similar to nucleoside analogs which target the enzyme reverse 
transcriptase, tenofovir DF acts as a false building block. 
Unlike the nucleoside analogs, it is monophosphorylated 
and therefore referred to as a nucleotide analog. In the 902 
and 907 studies, in which tenofovir was added to an existing 
HAART, the viral load fell by approximately 0.6 logs after 48 
weeks (Schooley et al 2002; Squires et al 2003). Equivalent 
potency comparing tenofovir to d4T (with a backbone regimen 
of 3TC + efavirenz) in treatment-naive patients was shown in 
the 903 Study. Especially side effects such as polyneuropathy 
and lipid changes were signiﬁ  cantly reduced when tenofovir 
was used. Investigator-reported lipodystrophy was less com-
mon in the tenofovir DF group compared with the stavudine 
group (9 [3%] of 299 vs 58 [19%] of 301, p   0.001) (Gallant 
et al 2004). In 2001, the drug was approved and is now widely 
used in antiretroviral therapies. Several studies have recently 
shown an improvement of lipid proﬁ  les, serum lactate, and 
lipodystrophy in HIV-positive patients after switch to teno-
fovir (Llibre et al 2006; Claas et al 2007). The RAVE study, 
a randomized, open-label, comparative study of switching 
from a thymidine nucleoside analog to either tenofovir DF or 
abacavir in 105 individuals with clinically evident lipoatrophy, 
showed signiﬁ  cant improvement in limb fat mass over 48 
weeks in both groups. It should be mentioned that mean 
total cholesterol, low density lipoprotein cholesterol, and Therapeutics and Clinical Risk Management 2008:4(4) 575
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triglycerides improved modestly with switching to tenofovir 
DF but were unchanged with abacavir (Moyle et al 2006).
However, in recent years conﬂ  icting data about the poten-
tial risk of nephrotoxicity associated with a mild to moderate 
disturbance of renal function, as well as several cases of 
renal failure, on tenofovir have been published. At the end of 
study 903 no signiﬁ  cant differences in mean serum creatinine 
levels among 299 patients treated with tenofovir, efavirenz, 
and lamivudine and 303 patients treated with stavudine efa-
virenz and lamivudine could be measured. Only 4 patients 
experienced a grade 1 creatinine elevation ( 0.5 mg/dL from 
baseline) in the tenofovir DF group, compared with 2 patients 
in the stavudine group (difference ns) (Izzedine et al 2005). 
Nevertheless other studies found that patients treated with a 
tenofovir DF-containing regimen had a small but signiﬁ  cantly 
greater decline in estimated creatinine clearance compared 
to individuals who received an alternative NRTI-containing 
regimen (–7.48 mL/min per 1.73 m2 versus –0.87 mL/min 
per 1.73 m2; p = 0.036) (Julg et al 2005; Gallant et al 2005). 
Gilead Sciences Inc., the manufacturer of tenofovir, has 
since recommended that patients with renal disease require 
dosing interval adjustments (300 mg 3 times per week) 
when the creatinine clearance is less than 50 mL/min and 
avoidance of tenofovir when the glomerular ﬁ  ltration rate 
(GFR) is less than 30 mL/min. Nevertheless renal function 
in all patients on tenofovir-containing regimens should be 
monitored regularly.
Another concern with tenofovir was raised by the obser-
vation of Schmid and colleagues, who found a signiﬁ  cant 
association between the use of tenofovir and the presence of 
the enzyme variant “macroenzyme creatine kinase type 2” 
(Macro CK2). Electrophoresis and immunoblotting demon-
strated that the Macro CK2 in TDF-treated patients consisted 
of the ubiquitous mitochondrial creative kinase (uMtCK) 
suggesting that the appearance of uMtCK in these patients 
might be a ﬁ  rst indicator of mitochondrial toxicity of TDF 
in the kidney (Schmid et al 2006).
Study 903 at week 144 showed furthermore a signiﬁ  cantly 
greater mean percentage decrease from baseline in bone min-
eral density (BMD) at the lumbar spine in patients receiving 
tenofovir + lamivudine + efavirenz (–2.2% ± 3.9%) compared 
with patients receiving stavudine + lamivudine + efavirenz 
(–1.0% ± 4.6%). In total, 28% of tenofovir-treated patients 
versus 21% of the stavudine-treated patients lost at least 5% 
of BMD at the spine or 7% of BMD at the hip.
One explanation could be an increased bone turnover, 
as a signiﬁ  cant increases in biochemical markers of bone 
metabolism such as alkaline phosphatase, serum osteocalcin, 
and serum C-telopeptide could be observed in the group on 
a tenofovir-containing regimen compared with the stavudine 
group (Gallant et al 2004).
In terms of drug resistance, which will be discussed later, 
the mutation K65R is selected by tenofovir and confers a 2- to 
4-fold reduced susceptibility to this drug. However the inci-
dence of K65R is low (3%) and has not been observed in clini-
cal trials with the concomitant use of tenofovir and FTC.
Emtricitabine (FTC)
Another NRTI, FTC is a pyrimidine nucleoside analog. FTC 
is similar to lamivudine (3TC) but seems to be more effective 
in in vivo studies and has a longer half-life. Several phases 3 
studies have demonstrated equal or superior activity of once-
daily administration of FTC, when compared head-to-head 
with activity of stavudine and 3TC. In the FTC-301 study, 
FTC, didanosine, and efavirenz were compared with stavu-
dine, didanosine, and efavirenz. Baseline characteristics were 
no different between the two groups. After 60 weeks, 76% of 
patients in the FTC arm had achieved and maintained HIV 
RNA loads of  50 copies/mL, compared with 54% in the 
stavudine arm (p   0.001) (Saag et al 2004). Because renal 
excretion of unchanged drug is the principal route of FTC 
elimination, the potential of FTC to cause metabolic drug 
interactions is low. No speciﬁ  c drug interactions have been 
reported in the literature. Development of drug resistance to 
FTC is comparable to that observed with 3TC. Used as mono-
therapy, a single point mutation at position 184 of reverse 
transcriptase develops rapidly and confers cross-resistance to 
3TC, but other nucleoside agents retain their activity (Sanne 
et al 2002; Rousseau et al 2003).
Truvada® (tenofovir DF/emtricitabine)
In 2005, a ﬁ  xed-dose combination of FTC (200 mg) and 
tenofovir (300 mg) was licensed and has been widely used 
since The combination of tenofovir + FTC (administered 
as separate tablets) plus efavirenz (n = 258 patients) was 
superior to zidovudine + 3TC (administered as a ﬁ  xed-dose 
combination with combivir), and efavirenz (n = 259 patients) 
in study 934. Results at 48 week revealed that 84% of the 
tenofovir-FTC group achieved HIV RNA loads of  400 
copies/mL, compared with 73% of the zidovudine-3TC 
group (p = 0.002) (Gallant et al 2006). Continued follow-up 
through week 96 demonstrated that patients treated in the 
tenofovir DF/emtricitabine arm continued to have higher rates 
of viral suppression (75%), versus patients in the zidovu-
dine/lamivudine arm (62%) in maintaining HIV RNA levels 
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tenofovir DF/emtricitabine showed additionally greater gains 
in CD4 cell counts at week 96 (mean increase, 270 cells/mm3 
versus 237 cells/mm3; p = 0.036, respectively).
Nevertheless a limitation should be mentioned, as a higher 
percentage of patients in the zidovudine-3TC group discon-
tinued the therapy prematurely (9%) than in the tenofovir-
FTC group (4%). Adverse events of grade 2–4 occurred in 
~72% of both groups, and most commonly included nausea 
(7%–9%), dizziness (7%–8%), fatique (8%), and diarrhea 
(5%–8%), but signiﬁ  cantly more patients in the zidovudine/
lamivudine group experienced a treatment-limiting toxicity 
(11% versus 5%; p = 0.008); anemia was the most common 
cause (14 versus 0 subjects in the emtricitabine/tenofovir 
DF group, p   0.001).
Fourteen patients in the tenofovir DF/emtricitabine group 
versus 27 in the zidovudine/lamivudine group met the criteria 
for treatment failure in study 934 and had genotypic data for 
drug resistance available after 96 weeks of therapy (Pozniak 
et al 2006). Efavirenz resistance mutations were most com-
mon (n = 10), followed by the M184V/I mutation, for those 
patients who were receiving tenofovir DF/emtricitabine. It 
should be mentioned that M184 occurred at a lower rate in 
patients on tenofovir DF/emtricitabine compared with the 
zidovudine/lamivudine group. However, the feared K65R 
mutation did not arise in any patient, but study 903, which 
evaluated a combination of efavirenz and tenofovir DF with 
lamivudine instead of emtricitabine, 8 out of 299 (2.7%) 
patients developed the K65R (Margot et al 2006).
Atripla™
Atripla™ combines the individual strengths and weaknesses 
of these compounds. Of all combination therapies available 
at the moment, Atripla™ offers the most convenient dosing 
schedule and the fewest number of pills. The combination 
efavirenz/emtricitabine/tenofovir DF was in general much 
better tolerated and caused signiﬁ  cantly less body fat change 
compared with the well-known mainstay zidovudine/lami-
vudine. In respect of these qualities, it seems to be more 
likely that patients will show a higher degree of adherence 
to this regimen compared with commonly available PI-based 
therapies. The concerns about the higher risk of missed doses 
in a once-daily regimen do not seem be proven, but clinical 
results should be awaited.
Current international treatment guidelines recommend a 
ﬁ  xed-dose dual-NRTI backbone of emtricitabine/tenofovir 
DF or zidovudine/lamivudine combined with either efavirenz 
or a boosted PI for initial therapy of treatment-naive patients. 
Choosing efavirenz as combination for the nuke backbone 
in Atripla™ is supported by the ACTG 5142 study, which 
demonstrated superior efﬁ  cacy and durability of an efavirenz-
based regimen compared with a lopinavir-based combination. 
Choosing tenofovir DF/emtricitabine as the nuke backbone 
for efavirenz was supported by the 934 study, which showed 
that after 48 weeks, more patients treated with tenofovir 
DF/emtricitabine had viral suppression (84% versus 73%; 
p = 0.002) and fewer treatment-limiting toxicities (9% versus 
4%) than the zidovudine/lamivudine arm (Galant 2006).
Finally, some side effects could be a limiting factor in 
using Atripla™. Tenofovir DF has shown a potential risk of 
nephrotoxicity although no association has been observed in 
clinical trials with long-term follow-up. Nevertheless mul-
tiple cases of acute renal failure and Fanconi’s syndrome have 
been reported and several studies have shown a decrease in 
the estimated GFR. These cases occurred mainly in patients 
with pre-existing renal diseases. Therefore, patients should 
receive a baseline renal function evaluation prior to receiving 
Atripla™, and regular monitoring of renal function during the 
therapy. Those patients with estimated GFR  50 mL/min 
should receive an alternative therapy.
As mentioned, efavirenz is teratogenic and should be 
avoided in pregnancy and carefully used in women of repro-
ductive age. Additionally the use of Atripla™ in patients with 
pre-existing psychiatric disorders should be evaluated in 
each case, as conditions may exacerbate during therapy with 
efavirenz. Common mild CNS complaints under efavirenz 
are self-limiting in most patients but should be monitored 
and eventually the therapy must be switched.
In summary, Atripla™ represents the “one-pill-daily” 
version of a widely used antiretroviral drug combination, 
pooling potent efﬁ  cacy with a beneﬁ  cial tolerability and 
safety proﬁ  le. Due to its unique dosing schedule it will 
be a ﬁ  rst choice therapy in therapy naive patients. Drug 
interaction studies using the Atripla™ formulation remain to 
be conducted as well as directly comparative studies with 
other drug combinations.
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